[
  {
    "ts": "2026-01-16T01:35:40+00:00",
    "headline": "Dow Jones Futures: Market Fades Despite Taiwan Semi, Goldman Lifting Chips, Banks",
    "summary": "The stock market rallied Thursday on Taiwan Semiconductor and Goldman Sachs earnings, but pared gains substantially.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-taiwan-semi-goldman-sachs-chips-banks-amd/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "ab113621-4f87-39b5-9977-f4517adc6e6e",
      "content": {
        "id": "ab113621-4f87-39b5-9977-f4517adc6e6e",
        "contentType": "STORY",
        "title": "Dow Jones Futures: Market Fades Despite Taiwan Semi, Goldman Lifting Chips, Banks",
        "description": "",
        "summary": "The stock market rallied Thursday on Taiwan Semiconductor and Goldman Sachs earnings, but pared gains substantially.",
        "pubDate": "2026-01-16T01:35:40Z",
        "displayTime": "2026-01-16T01:35:40Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ab113621-4f87-39b5-9977-f4517adc6e6e/dow-jones-futures-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/4112a1f6727dc8de646aec531b3068c8",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SWvtqlu9HmfGA.86rSNWqg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/4112a1f6727dc8de646aec531b3068c8.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DJgrKtvby8.x8MW8umXTJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/4112a1f6727dc8de646aec531b3068c8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-taiwan-semi-goldman-sachs-chips-banks-amd/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "TSM"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "JBHT"
            },
            {
              "symbol": "BLK"
            },
            {
              "symbol": "DY"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T00:05:00+00:00",
    "headline": "3 Unstoppable Stocks to Buy in 2026 and Hold Forever",
    "summary": "These stocks are leaders in their respective industries, and they have excellent fundamentals.",
    "url": "https://www.fool.com/investing/2026/01/15/3-unstoppable-stocks-to-buy-in-2026-and-hold-forev/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "93b21784-96c7-356a-a31a-3ccd4b2b81c7",
      "content": {
        "id": "93b21784-96c7-356a-a31a-3ccd4b2b81c7",
        "contentType": "STORY",
        "title": "3 Unstoppable Stocks to Buy in 2026 and Hold Forever",
        "description": "",
        "summary": "These stocks are leaders in their respective industries, and they have excellent fundamentals.",
        "pubDate": "2026-01-16T00:05:00Z",
        "displayTime": "2026-01-16T00:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/06305271c9aee7141d716b8a6691f55e",
          "originalWidth": 1400,
          "originalHeight": 1078,
          "caption": "A family reviewing financial results with an advisor.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ytNoMrR6wzz5NOgp1ksgGg--~B/aD0xMDc4O3c9MTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/06305271c9aee7141d716b8a6691f55e.cf.webp",
              "width": 1400,
              "height": 1078,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jZU8yEiGEYXwlZ2EUfM7sw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/06305271c9aee7141d716b8a6691f55e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/15/3-unstoppable-stocks-to-buy-in-2026-and-hold-forev/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-unstoppable-stocks-buy-2026-000500585.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AXP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T12:43:12+00:00",
    "headline": "Dow Jones Futures: Techs Lead, AMD Eyes Buy Point In Powerful Week",
    "summary": "Techs lead futures Friday but after Thursday's market fade. AMD is eyeing an early buy point again on Taiwan Semiconductor optimism.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-amd-buy-point-taiwan-semiconductor/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "ab113621-4f87-39b5-9977-f4517adc6e6e",
      "content": {
        "id": "ab113621-4f87-39b5-9977-f4517adc6e6e",
        "contentType": "STORY",
        "title": "Dow Jones Futures: Techs Lead, AMD Eyes Buy Point In Powerful Week",
        "description": "",
        "summary": "Techs lead futures Friday but after Thursday's market fade. AMD is eyeing an early buy point again on Taiwan Semiconductor optimism.",
        "pubDate": "2026-01-16T12:43:12Z",
        "displayTime": "2026-01-16T12:43:12Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ab113621-4f87-39b5-9977-f4517adc6e6e/dow-jones-futures-techs.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/67d8022baa795c37d0fdd029d7ce1dcb",
          "originalWidth": 1119,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e2oWglvPtS1RRg9sQ7rEAw--~B/aD01NzI7dz0xMTE5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/67d8022baa795c37d0fdd029d7ce1dcb.cf.webp",
              "width": 1119,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rDo3lmxQhsauCEsLNuUoTw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/67d8022baa795c37d0fdd029d7ce1dcb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-amd-buy-point-taiwan-semiconductor/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMD"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "TSM"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JBHT"
            },
            {
              "symbol": "BLK"
            },
            {
              "symbol": "DY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T12:59:21+00:00",
    "headline": "Dow Jones Futures: Techs Rise, AMD Eyes Buy Point In Powerful Week",
    "summary": "Techs lead futures Friday but after Thursday's market fade. AMD is eyeing an early buy point again on Taiwan Semiconductor optimism.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-amd-buy-point-taiwan-semiconductor/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "ab113621-4f87-39b5-9977-f4517adc6e6e",
      "content": {
        "id": "ab113621-4f87-39b5-9977-f4517adc6e6e",
        "contentType": "STORY",
        "title": "Dow Jones Futures: Techs Rise, AMD Eyes Buy Point In Powerful Week",
        "description": "",
        "summary": "Techs lead futures Friday but after Thursday's market fade. AMD is eyeing an early buy point again on Taiwan Semiconductor optimism.",
        "pubDate": "2026-01-16T12:59:21Z",
        "displayTime": "2026-01-16T12:59:21Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ab113621-4f87-39b5-9977-f4517adc6e6e/dow-jones-futures-techs.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/67d8022baa795c37d0fdd029d7ce1dcb",
          "originalWidth": 1119,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e2oWglvPtS1RRg9sQ7rEAw--~B/aD01NzI7dz0xMTE5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/67d8022baa795c37d0fdd029d7ce1dcb.cf.webp",
              "width": 1119,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rDo3lmxQhsauCEsLNuUoTw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/67d8022baa795c37d0fdd029d7ce1dcb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-amd-buy-point-taiwan-semiconductor/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMD"
            },
            {
              "symbol": "GS"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "TSM"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JBHT"
            },
            {
              "symbol": "BLK"
            },
            {
              "symbol": "DY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T12:37:00+00:00",
    "headline": "Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss",
    "summary": "Novo Nordisk  traded higher in the U.S. after the U.K.’s healthcare regulator approved a higher dose of Novo’s blockbuster weight-loss drug, Wegovy.  The Medicines and Healthcare Products Regulatory Agency said Friday that it had approved a maximum dose of up to 7.2 milligrams per week of semaglutide, a step up from the former 2.4 mg limit.  The dose is to be administered as three separate injections, strictly in adult patients with obesity.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-wegovy-uk-160f3149?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "87d12fa1-2b0f-30b7-b2db-df2929574932",
      "content": {
        "id": "87d12fa1-2b0f-30b7-b2db-df2929574932",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss",
        "description": "",
        "summary": "Novo Nordisk  traded higher in the U.S. after the U.K.’s healthcare regulator approved a higher dose of Novo’s blockbuster weight-loss drug, Wegovy.  The Medicines and Healthcare Products Regulatory Agency said Friday that it had approved a maximum dose of up to 7.2 milligrams per week of semaglutide, a step up from the former 2.4 mg limit.  The dose is to be administered as three separate injections, strictly in adult patients with obesity.",
        "pubDate": "2026-01-16T12:37:00Z",
        "displayTime": "2026-01-16T12:37:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/87d12fa1-2b0f-30b7-b2db-df2929574932/novo-nordisk-stock-rises.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/6fe5ab2e01146a80ab08daa7cab29f6b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D3ft5vZiG3XEmnoDBPlGCA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/6fe5ab2e01146a80ab08daa7cab29f6b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/twTtSJOUK960CY9joq9utg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/6fe5ab2e01146a80ab08daa7cab29f6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-wegovy-uk-160f3149?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T15:05:00+00:00",
    "headline": "Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know.",
    "summary": "The high-powered duo is teaming up to build and equip a $1 billion research facility in California.",
    "url": "https://www.fool.com/investing/2026/01/16/nvidia-eli-lilly-partner-1-billion-lab-ai/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "5532f875-52fc-3818-8172-12461e020831",
      "content": {
        "id": "5532f875-52fc-3818-8172-12461e020831",
        "contentType": "STORY",
        "title": "Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know.",
        "description": "",
        "summary": "The high-powered duo is teaming up to build and equip a $1 billion research facility in California.",
        "pubDate": "2026-01-16T15:05:00Z",
        "displayTime": "2026-01-16T15:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/cb51c82ca7efd1741b3a9800d1f34b66",
          "originalWidth": 1400,
          "originalHeight": 840,
          "caption": "Nvidia showcase of artificial intelligence AI technology.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zfQboJBXbYIeyQf2syqIPA--~B/aD04NDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/cb51c82ca7efd1741b3a9800d1f34b66.cf.webp",
              "width": 1400,
              "height": 840,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w9WJRO50vdO6BbQx_PJvDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/cb51c82ca7efd1741b3a9800d1f34b66.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/16/nvidia-eli-lilly-partner-1-billion-lab-ai/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nvidia-eli-lilly-partnering-1-150500390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T14:39:47+00:00",
    "headline": "Stocks to Watch Friday: J.B. Hunt, PNC, Verizon",
    "summary": "↘️ J.B. Hunt Transport Services (JBHT): The logistics company recorded lower quarterly revenue, as transcontinental load volumes declined. Shares fell about 2% in early trading. ↗️ Novo Nordisk (DK:NOVO.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-16-2026/card/stocks-to-watch-friday-j-b-hunt-pnc-verizon-keWejK8riJCb6jCEHgUB?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "330000a2-6ff5-3122-b4eb-70477dd82a50",
      "content": {
        "id": "330000a2-6ff5-3122-b4eb-70477dd82a50",
        "contentType": "STORY",
        "title": "Stocks to Watch Friday: J.B. Hunt, PNC, Verizon",
        "description": "",
        "summary": "↘️ J.B. Hunt Transport Services (JBHT): The logistics company recorded lower quarterly revenue, as transcontinental load volumes declined. Shares fell about 2% in early trading. ↗️ Novo Nordisk (DK:NOVO.",
        "pubDate": "2026-01-16T14:39:47Z",
        "displayTime": "2026-01-16T14:39:47Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/330000a2-6ff5-3122-b4eb-70477dd82a50/stocks-to-watch-friday-j-b-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/c6b31ecb502ee83765a07d2fda65b606",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mKj9JCTsguQfKQalQ9tQlQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/c6b31ecb502ee83765a07d2fda65b606.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CMiwrHtcSqYCP2MAqtVvSA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/c6b31ecb502ee83765a07d2fda65b606.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-16-2026/card/stocks-to-watch-friday-j-b-hunt-pnc-verizon-keWejK8riJCb6jCEHgUB?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JBHT"
            },
            {
              "symbol": "PNC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "VZ"
            },
            {
              "symbol": "MTB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T14:33:36+00:00",
    "headline": "Why A 'Solid' First Week For Oral Wegovy Bodes Well For Novo And Lilly",
    "summary": "Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo Nordisk stock jumped.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "4f216d49-3a56-3631-9ffc-9915feeace4b",
      "content": {
        "id": "4f216d49-3a56-3631-9ffc-9915feeace4b",
        "contentType": "STORY",
        "title": "Why A 'Solid' First Week For Oral Wegovy Bodes Well For Novo And Lilly",
        "description": "",
        "summary": "Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo Nordisk stock jumped.",
        "pubDate": "2026-01-16T14:33:36Z",
        "displayTime": "2026-01-16T14:33:36Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/4f216d49-3a56-3631-9ffc-9915feeace4b/why-a-solid-first-week-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f0775872a205208a6c27ac4f3494687a",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WfRAppdYv7_ty1Tj9_jNAQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/f0775872a205208a6c27ac4f3494687a.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_KSMIExddZxZ3zkymfHxQw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f0775872a205208a6c27ac4f3494687a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T15:28:49+00:00",
    "headline": "Trump’s New Prescription Plan vs. Mark Cuban’s: Experts Weigh In",
    "summary": "Fed up with soaring prescription drug costs, billionaire Mark Cuban launched the Mark Cuban CostPlus Drug Company, an online pharmacy offering low-cost generic medications, with co-founder Alex...",
    "url": "https://finance.yahoo.com/news/trump-prescription-plan-vs-mark-152849620.html",
    "source": "GOBankingRates",
    "provider": "yfinance",
    "raw": {
      "id": "8d717045-047f-389a-a591-79a457b191c4",
      "content": {
        "id": "8d717045-047f-389a-a591-79a457b191c4",
        "contentType": "STORY",
        "title": "Trump’s New Prescription Plan vs. Mark Cuban’s: Experts Weigh In",
        "description": "",
        "summary": "Fed up with soaring prescription drug costs, billionaire Mark Cuban launched the Mark Cuban CostPlus Drug Company, an online pharmacy offering low-cost generic medications, with co-founder Alex...",
        "pubDate": "2026-01-16T15:28:49Z",
        "displayTime": "2026-01-16T15:28:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/gobankingrates_644/cbdb536426180a7b7f06b0c3f34381df",
          "originalWidth": 1920,
          "originalHeight": 1081,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u2R0M6se5WPv7R2KrBB4ow--~B/aD0xMDgxO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/gobankingrates_644/cbdb536426180a7b7f06b0c3f34381df.cf.webp",
              "width": 1920,
              "height": 1081,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z.hft9xpqbIsyFjdWWtlOQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/gobankingrates_644/cbdb536426180a7b7f06b0c3f34381df.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GOBankingRates",
          "url": "https://www.gobankingrates.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/trump-prescription-plan-vs-mark-152849620.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/trump-prescription-plan-vs-mark-152849620.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T15:22:44+00:00",
    "headline": "Novo shares jump on 'encouraging' Wegovy pill scripts data, analysts say",
    "summary": "<body><p>STORY: Novo Nordisk shares rose over 5% on Friday to highs last seen in October.</p><p>Investors bought in on what analysts called 'encouraging' early U.S. data for its Wegovy pill.</p><p>The weight-loss giant hopes the pill will help it regain ground in the obesity drug race.</p><p>It was made available to U.S. patients from January 5 after gaining approval from regulators last month.</p><p>The market is closely watching early sales for signs of strength or weakness.</p><p>And investors want to see how Novo uses its first-to-market lead against rival Eli Lilly.</p><p>It's positive news for Novo CEO Mike Doustdar, who took over last year.</p><p>He wants to attract new consumers with the pill.</p><p>Novo aims to recover from a challenging last year of profit warnings and sliding shares.</p><p>Investors sold off in 2025 when sales growth of Novo's injectable medication slowed.</p></body>",
    "url": "https://finance.yahoo.com/video/novo-shares-jump-encouraging-wegovy-152244850.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "d3d469c9-d478-31dc-8b4e-8ae3b0abe479",
      "content": {
        "id": "d3d469c9-d478-31dc-8b4e-8ae3b0abe479",
        "contentType": "VIDEO",
        "title": "Novo shares jump on 'encouraging' Wegovy pill scripts data, analysts say",
        "description": "<title><body><p>STORY: Novo Nordisk shares rose over 5% on Friday to highs last seen in October.</p><p>Investors bought in on what analysts called 'encouraging' early U.S. data for its Wegovy pill.</p><p>The weight-loss giant hopes the pill will help it regain ground in the obesity drug race.</p><p>It was made available to U.S. patients from January 5 after gaining approval from regulators last month.</p><p>The market is closely watching early sales for signs of strength or weakness.</p><p>And investors want to see how Novo uses its first-to-market lead against rival Eli Lilly.</p><p>It's positive news for Novo CEO Mike Doustdar, who took over last year.</p><p>He wants to attract new consumers with the pill.</p><p>Novo aims to recover from a challenging last year of profit warnings and sliding shares.</p><p>Investors sold off in 2025 when sales growth of Novo's injectable medication slowed.</p></body></title>",
        "summary": "<body><p>STORY: Novo Nordisk shares rose over 5% on Friday to highs last seen in October.</p><p>Investors bought in on what analysts called 'encouraging' early U.S. data for its Wegovy pill.</p><p>The weight-loss giant hopes the pill will help it regain ground in the obesity drug race.</p><p>It was made available to U.S. patients from January 5 after gaining approval from regulators last month.</p><p>The market is closely watching early sales for signs of strength or weakness.</p><p>And investors want to see how Novo uses its first-to-market lead against rival Eli Lilly.</p><p>It's positive news for Novo CEO Mike Doustdar, who took over last year.</p><p>He wants to attract new consumers with the pill.</p><p>Novo aims to recover from a challenging last year of profit warnings and sliding shares.</p><p>Investors sold off in 2025 when sales growth of Novo's injectable medication slowed.</p></body>",
        "pubDate": "2026-01-16T15:22:44Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/mGmrf_Otk73Rl8OE27qhTQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/dac569c4-d917-4e93-bf76-2fa0ba3b52e8/main/1280x720/26s331ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J0..7lXaX9PKvk87VwUUHw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/dac569c4-d917-4e93-bf76-2fa0ba3b52e8/main/1280x720/26s331ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oekncx86Zz2iItz1507E1g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/dac569c4-d917-4e93-bf76-2fa0ba3b52e8/main/1280x720/26s331ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-shares-jump-encouraging-wegovy-152244850.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-shares-jump-encouraging-wegovy-152244850.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T14:00:08+00:00",
    "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finance.yahoo.com/news/investors-heavily-search-eli-lilly-140008791.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a8ac6215-25bd-39d9-9cbe-159537b78327",
      "content": {
        "id": "a8ac6215-25bd-39d9-9cbe-159537b78327",
        "contentType": "STORY",
        "title": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know",
        "description": "",
        "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "pubDate": "2026-01-16T14:00:08Z",
        "displayTime": "2026-01-16T14:00:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R44DoTZV_0PRYb38xOZB.w--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XH9RX1D8m2SgxOWLNEKDKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-heavily-search-eli-lilly-140008791.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-heavily-search-eli-lilly-140008791.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T17:13:25+00:00",
    "headline": "Jim Cramer on Structure Therapeutics: “I Don’t Want to Touch It”",
    "summary": "Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about the stock, Cramer commented: “Oh, okay, so this is a, they have a deal with Roche, and therefore, I think it’s a legitimate idea, but, boy, the stock fully reflects that deal. I don’t want to […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-structure-therapeutics-don-171325935.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "be176e38-15c4-33e1-b2c4-a3dc907f0b0e",
      "content": {
        "id": "be176e38-15c4-33e1-b2c4-a3dc907f0b0e",
        "contentType": "STORY",
        "title": "Jim Cramer on Structure Therapeutics: “I Don’t Want to Touch It”",
        "description": "",
        "summary": "Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about the stock, Cramer commented: “Oh, okay, so this is a, they have a deal with Roche, and therefore, I think it’s a legitimate idea, but, boy, the stock fully reflects that deal. I don’t want to […]",
        "pubDate": "2026-01-16T17:13:25Z",
        "displayTime": "2026-01-16T17:13:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/dc5a2bcb6b4c16a43cb5b4ba98feb139",
          "originalWidth": 600,
          "originalHeight": 800,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BXr9A2_qJNwaN79dQdOX5w--~B/aD04MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/dc5a2bcb6b4c16a43cb5b4ba98feb139.cf.webp",
              "width": 600,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FUUKa_G6motb68kvXUoCZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/dc5a2bcb6b4c16a43cb5b4ba98feb139.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-structure-therapeutics-don-171325935.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-structure-therapeutics-don-171325935.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GPCR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T16:48:18+00:00",
    "headline": "Novo's Wegovy Pill Is Following In Zepbound's Footsteps — And It's Only Been One Week",
    "summary": "Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo Nordisk stock jumped.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "4f216d49-3a56-3631-9ffc-9915feeace4b",
      "content": {
        "id": "4f216d49-3a56-3631-9ffc-9915feeace4b",
        "contentType": "STORY",
        "title": "Novo's Wegovy Pill Is Following In Zepbound's Footsteps — And It's Only Been One Week",
        "description": "",
        "summary": "Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo Nordisk stock jumped.",
        "pubDate": "2026-01-16T16:48:18Z",
        "displayTime": "2026-01-16T16:48:18Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/4f216d49-3a56-3631-9ffc-9915feeace4b/novo-s-wegovy-pill-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f0775872a205208a6c27ac4f3494687a",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WfRAppdYv7_ty1Tj9_jNAQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/f0775872a205208a6c27ac4f3494687a.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_KSMIExddZxZ3zkymfHxQw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f0775872a205208a6c27ac4f3494687a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T16:19:00+00:00",
    "headline": "Novo Nordisk’s Wegovy Weight Loss Pill Has a Strong Launch—and Other Reasons the Stock Is Rising",
    "summary": "Novo Nordisk  traded higher in the U.S. following a string of wins for the drugmaker’s star weight-loss treatment, Wegovy.  The U.K.’s healthcare regulator said Friday that it had approved a higher dose of semaglutide, which sold under the brand name Wegovy for weight loss.  The maximum dose of up to 7.2 milligrams per week is a significant step up from the former 2.4 mg limit.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-wegovy-pill-nvo-uk-160f3149?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "87d12fa1-2b0f-30b7-b2db-df2929574932",
      "content": {
        "id": "87d12fa1-2b0f-30b7-b2db-df2929574932",
        "contentType": "STORY",
        "title": "Novo Nordisk’s Wegovy Weight Loss Pill Has a Strong Launch—and Other Reasons the Stock Is Rising",
        "description": "",
        "summary": "Novo Nordisk  traded higher in the U.S. following a string of wins for the drugmaker’s star weight-loss treatment, Wegovy.  The U.K.’s healthcare regulator said Friday that it had approved a higher dose of semaglutide, which sold under the brand name Wegovy for weight loss.  The maximum dose of up to 7.2 milligrams per week is a significant step up from the former 2.4 mg limit.",
        "pubDate": "2026-01-16T16:19:00Z",
        "displayTime": "2026-01-16T16:19:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/87d12fa1-2b0f-30b7-b2db-df2929574932/novo-nordisk%E2%80%99s-wegovy-weight.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/6fe5ab2e01146a80ab08daa7cab29f6b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D3ft5vZiG3XEmnoDBPlGCA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/6fe5ab2e01146a80ab08daa7cab29f6b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/twTtSJOUK960CY9joq9utg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/6fe5ab2e01146a80ab08daa7cab29f6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-wegovy-pill-nvo-uk-160f3149?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T18:27:40+00:00",
    "headline": "Stock Market Today: Dow, S&P Waffle As Battered Obesity Drug Giant Soars (Live Coverage)",
    "summary": "The Dow Jones Industrial Average and other major stock indexes turned positive in afternoon trading Friday, as Wall Street looked ahead to a three-day weekend. Among the winners was obesity drug stock Novo Nordisk, which surged on the stock market today.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-record-highs-nvidia-nvda-stock/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "3eb151cc-5e80-3fdc-935f-8ef57b39799b",
      "content": {
        "id": "3eb151cc-5e80-3fdc-935f-8ef57b39799b",
        "contentType": "STORY",
        "title": "Stock Market Today: Dow, S&P Waffle As Battered Obesity Drug Giant Soars (Live Coverage)",
        "description": "",
        "summary": "The Dow Jones Industrial Average and other major stock indexes turned positive in afternoon trading Friday, as Wall Street looked ahead to a three-day weekend. Among the winners was obesity drug stock Novo Nordisk, which surged on the stock market today.",
        "pubDate": "2026-01-16T18:27:40Z",
        "displayTime": "2026-01-16T18:27:40Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3eb151cc-5e80-3fdc-935f-8ef57b39799b/stock-market-today-dow-s-p.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/b9715ff1a750947c2a66c66577928376",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LyR0Ezz6fO2zKMIemxL86w--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/b9715ff1a750947c2a66c66577928376.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xkqimy.zH7QZX4upB8znuA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/b9715ff1a750947c2a66c66577928376.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-record-highs-nvidia-nvda-stock/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T18:06:00+00:00",
    "headline": "Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?",
    "summary": "The choice isn't that hard.",
    "url": "https://www.fool.com/investing/2026/01/16/eli-lilly-vs-novo-nordisk-which-is-the-better-buy/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1e50f947-8511-3e1d-88ca-270707cee00d",
      "content": {
        "id": "1e50f947-8511-3e1d-88ca-270707cee00d",
        "contentType": "STORY",
        "title": "Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?",
        "description": "",
        "summary": "The choice isn't that hard.",
        "pubDate": "2026-01-16T18:06:00Z",
        "displayTime": "2026-01-16T18:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4a28ed5ba849f787c02200f935b1f53f",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Person working at a desk.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cww36vWAua.rWyggqI9xwg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4a28ed5ba849f787c02200f935b1f53f.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PvJf5z.9AFfTvNJeeBHHVQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4a28ed5ba849f787c02200f935b1f53f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/16/eli-lilly-vs-novo-nordisk-which-is-the-better-buy/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-vs-novo-nordisk-180600830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T17:59:51+00:00",
    "headline": "Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus",
    "summary": "Novo Nordisk Rallies After Early U.S. Demand Signals for Wegovy Pill.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-stock-jumps-wegovy-175951201.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "1678dbb3-94b0-38f5-8f5e-878b0aa195e3",
      "content": {
        "id": "1678dbb3-94b0-38f5-8f5e-878b0aa195e3",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus",
        "description": "",
        "summary": "Novo Nordisk Rallies After Early U.S. Demand Signals for Wegovy Pill.",
        "pubDate": "2026-01-16T17:59:51Z",
        "displayTime": "2026-01-16T17:59:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-stock-jumps-wegovy-175951201.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-stock-jumps-wegovy-175951201.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T17:46:55+00:00",
    "headline": "Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer",
    "summary": "We recently published 10 Stocks Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer talked about. Pharma giant Novo Nordisk A/S (NYSE:NVO) created quite the buzz last month after its weight loss pill secured approval from the Food and Drug Administration (FDA), following which the shares jumped by […]",
    "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-battle-says-174655701.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "652774ec-7e55-3ccf-a2b3-0d21a56a7796",
      "content": {
        "id": "652774ec-7e55-3ccf-a2b3-0d21a56a7796",
        "contentType": "STORY",
        "title": "Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer",
        "description": "",
        "summary": "We recently published 10 Stocks Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer talked about. Pharma giant Novo Nordisk A/S (NYSE:NVO) created quite the buzz last month after its weight loss pill secured approval from the Food and Drug Administration (FDA), following which the shares jumped by […]",
        "pubDate": "2026-01-16T17:46:55Z",
        "displayTime": "2026-01-16T17:46:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/273ddf53b9b1b0964f663b55dda351d7",
          "originalWidth": 768,
          "originalHeight": 432,
          "caption": "Novo Nordisk (NVO) is \"in a Battle,\" Says Jim Cramer",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BBCAsmCgUUdntK_OANtalw--~B/aD00MzI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/273ddf53b9b1b0964f663b55dda351d7.cf.webp",
              "width": 768,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.u8.qK7bYr2wzn2C1jV1Qw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/273ddf53b9b1b0964f663b55dda351d7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-battle-says-174655701.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-battle-says-174655701.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T15:47:00+00:00",
    "headline": "LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling",
    "summary": "Eli Lilly stock declines after the FDA reportedly delays a decision on its obesity pill orforglipron, pushing the timeline to April and giving NVO more time.",
    "url": "https://finance.yahoo.com/news/lly-stock-falls-fda-reportedly-154700821.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "63715774-3a39-3307-8a2a-d2d96336d0ec",
      "content": {
        "id": "63715774-3a39-3307-8a2a-d2d96336d0ec",
        "contentType": "STORY",
        "title": "LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling",
        "description": "",
        "summary": "Eli Lilly stock declines after the FDA reportedly delays a decision on its obesity pill orforglipron, pushing the timeline to April and giving NVO more time.",
        "pubDate": "2026-01-16T15:47:00Z",
        "displayTime": "2026-01-16T15:47:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WtA490SSyXq.BB5XEEYFSg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BdQSUWaJAMCKg7gp75c9jQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lly-stock-falls-fda-reportedly-154700821.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lly-stock-falls-fda-reportedly-154700821.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T20:14:00+00:00",
    "headline": "From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development",
    "summary": "The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.",
    "url": "https://finance.yahoo.com/news/openai-offices-deal-eli-lilly-201400016.html",
    "source": "TechCrunch",
    "provider": "yfinance",
    "raw": {
      "id": "721593cb-5e78-35d7-af68-cfda36cadffa",
      "content": {
        "id": "721593cb-5e78-35d7-af68-cfda36cadffa",
        "contentType": "STORY",
        "title": "From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development",
        "description": "",
        "summary": "The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.",
        "pubDate": "2026-01-16T20:14:00Z",
        "displayTime": "2026-01-16T20:14:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/techcrunch_finance_785/3f5e08d2ec791ff8f8eebc2cd6aed023",
          "originalWidth": 2048,
          "originalHeight": 1366,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WZUBXCwyarAk_KzQUYGb0w--~B/aD0xMzY2O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/techcrunch_finance_785/3f5e08d2ec791ff8f8eebc2cd6aed023.cf.webp",
              "width": 2048,
              "height": 1366,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/h51gyO3kaIbcM.qmPItX7w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/techcrunch_finance_785/3f5e08d2ec791ff8f8eebc2cd6aed023.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TechCrunch",
          "url": "https://techcrunch.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/openai-offices-deal-eli-lilly-201400016.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/openai-offices-deal-eli-lilly-201400016.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "OPAI.PVT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]